Prelude Therapeutics Statistics
Total Valuation
PRLD has a market cap or net worth of $115.72 million. The enterprise value is $76.33 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PRLD has 76.13 million shares outstanding. The number of shares has increased by 2.37% in one year.
| Current Share Class | 43.75M |
| Shares Outstanding | 76.13M |
| Shares Change (YoY) | +2.37% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 5.85% |
| Owned by Institutions (%) | 8.55% |
| Float | 15.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.93 |
| Forward PS | n/a |
| PB Ratio | 1.46 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.31.
| Current Ratio | 3.21 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -103.99% and return on invested capital (ROIC) is -60.29%.
| Return on Equity (ROE) | -103.99% |
| Return on Assets (ROA) | -51.82% |
| Return on Invested Capital (ROIC) | -60.29% |
| Return on Capital Employed (ROCE) | -158.10% |
| Revenue Per Employee | $80,153 |
| Profits Per Employee | -$853,221 |
| Employee Count | 131 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.40% in the last 52 weeks. The beta is 1.06, so PRLD's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +43.40% |
| 50-Day Moving Average | 1.40 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 50.00 |
| Average Volume (20 Days) | 3,434,122 |
Short Selling Information
The latest short interest is 515,090, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 515,090 |
| Short Previous Month | 601,130 |
| Short % of Shares Out | 0.68% |
| Short % of Float | 3.27% |
| Short Ratio (days to cover) | 2.26 |
Income Statement
In the last 12 months, PRLD had revenue of $10.50 million and -$111.77 million in losses. Loss per share was -$1.47.
| Revenue | 10.50M |
| Gross Profit | 10.50M |
| Operating Income | -121.05M |
| Pretax Income | -111.77M |
| Net Income | -111.77M |
| EBITDA | -119.27M |
| EBIT | -121.05M |
| Loss Per Share | -$1.47 |
Full Income StatementBalance Sheet
The company has $54.96 million in cash and $17.85 million in debt, giving a net cash position of $37.10 million or $0.49 per share.
| Cash & Cash Equivalents | 54.96M |
| Total Debt | 17.85M |
| Net Cash | 37.10M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 58.53M |
| Book Value Per Share | 1.03 |
| Working Capital | 40.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$100.17 million and capital expenditures -$120,000, giving a free cash flow of -$100.29 million.
| Operating Cash Flow | -100.17M |
| Capital Expenditures | -120,000 |
| Free Cash Flow | -100.29M |
| FCF Per Share | -$1.32 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,152.85% |
| Pretax Margin | -1,064.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PRLD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.37% |
| Shareholder Yield | -2.37% |
| Earnings Yield | -98.53% |
| FCF Yield | -88.41% |
Analyst Forecast
The average price target for PRLD is $4.00, which is 163.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.00 |
| Price Target Difference | 163.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 26.62% |
| EPS Growth Forecast (5Y) | -11.76% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
